First Analysis Upgrades Cambrex Corporation (CBM) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Cambrex Reports Third Quarter 2016 Financial Results
November 4, 2016 7:00 AM EDT- Sales increased 8% in the quarter, full year sales and profit guidance increased -
- Acquisition of North Carolina based PharmaCore completed -
- Conference call at 8:30 a.m. ET on November 4, 2016 -
EAST RUTHERFORD, N.J., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the third quarter ended September 30, 2016.
Highlights
Sales increased... More


